Delving into the Latest Updates on INO-9112 with Synapse

Overview

Basic Info

Drug Type

DNA vaccine, Prophylactic vaccine

Synonyms-

Target

IL2RA

Mechanism

IL2RA agonists(Interleukin-2 receptor alpha chain agonists)

Therapeutic Areas

Infectious DiseasesDigestive System DisordersRespiratory Diseases

Active Indication-

Inactive Indication

COVID-19Hepatitis B, Chronic

Originator Organization

Inovio Pharmaceuticals, Inc.

Active Organization-

Inactive Organization

Inovio Pharmaceuticals, Inc.

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

This is an open label, phase 1 clinical trial of an intra-dermal booster dose of INO-4800 alone or in combination with INO-9112 followed by electroporation (EP) among healthy adults at least 18 years of age, who previously completed their primary immunization series with mRNA vaccines against SARS-CoV-2 within 6-12 months prior to the booster dose.

Start Date01 Oct 2022

Sponsor / Collaborator

Inovio Pharmaceuticals, Inc.

PACTR202206666476182

/ Unknown statusPhase 1

Phase 1 Open Label, Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Intradermal Booster Dose of INO-4800 Alone or in Combination With INO-9112 Followed by Electroporation, in Adults Who Completed a Primary Immunization Series Against SARS-CoV-2 With mRNA Vaccines

Start Date31 Aug 2022

Sponsor / Collaborator

Inovio Pharmaceuticals, Inc.

NCT02431312

/ CompletedPhase 1

Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients

This was an open-label study that evaluated the safety, tolerability, and immunogenicity of dose combinations of INO-1800 (DNA plasmids encoding Hepatitis B surface antigen [HBsAg] and Hepatitis B core antigen [HBcAg]) and INO-9112 (DNA plasmid encoding human interleukin 12) delivered by electroporation (EP) in 90 (ninety) nucleos(t)ide analogue treated participants.

Start Date12 Jan 2015

Sponsor / Collaborator

Inovio Pharmaceuticals, Inc.

100 Clinical Results associated with INO-9112

Login to view more data

100 Translational Medicine associated with INO-9112

Login to view more data

100 Patents (Medical) associated with INO-9112

Login to view more data

100 Deals associated with INO-9112

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 1	-	Inovio Pharmaceuticals, Inc.	01 Oct 2022
Hepatitis B, Chronic	Phase 1	US	Inovio Pharmaceuticals, Inc.	12 Jan 2015
Hepatitis B, Chronic	Phase 1	AU	Inovio Pharmaceuticals, Inc.	12 Jan 2015
Hepatitis B, Chronic	Phase 1	HK	Inovio Pharmaceuticals, Inc.	12 Jan 2015
Hepatitis B, Chronic	Phase 1	NZ	Inovio Pharmaceuticals, Inc.	12 Jan 2015
Hepatitis B, Chronic	Phase 1	PH	Inovio Pharmaceuticals, Inc.	12 Jan 2015
Hepatitis B, Chronic	Phase 1	SG	Inovio Pharmaceuticals, Inc.	12 Jan 2015
Hepatitis B, Chronic	Phase 1	TW	Inovio Pharmaceuticals, Inc.	12 Jan 2015
Hepatitis B, Chronic	Phase 1	TH	Inovio Pharmaceuticals, Inc.	12 Jan 2015